Notably, key pathways with significant effects on TAMs, such as CSF1-CSF1R axis, CCL2-CCR2 axis, and CD47-SIRPα axis, have very few or no clinical studies conducted in the context of bladder cancer. The gene discussed is CCL2; the disease is urinary bladder cancer.